SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025
BOSTON and ROLLE, Switzerland, Oct. 21, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today...
Cancer
Subtle Medical Announces Positive Findings from Proof-of-Concept Study with Bayer Investigating AI To Lower Gadolinium Dose in CE-MRI
MENLO PARK, Calif., Oct. 21, 2025 /PRNewswire/ -- Subtle Medical, Inc., a leader in AI-powered medical imaging solutions, today announced positive...
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for...
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for...
Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers
IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studiesFirst patient...
Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology
The 2026 Award is focused on research in paediatric oncology, specifically sarcomasPaediatric sarcomas are among the leading causes of cancer-related...
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO)...
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy...
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical...
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly...
Solenic Medical Announces Successful Use of Its AMF Technology Under FDA Compassionate Use Authorization
Company to Exhibit at American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting 2025DALLAS, Oct. 21, 2025 (GLOBE NEWSWIRE)...
Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers
Findings presented at European Society for Medical Oncology include models in solid tumors and hematologic malignanciesSOUTH SAN FRANCISCO, Calif., and...
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast...
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™...
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025...
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to...
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
CHATHAM, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated,...
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of...
Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Saint-Genis-Pouilly, France, 21 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment,...
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...